.svg)
Latest news
Scientific publications
#AACR2024 Brenus Pharma unveils promising and robust pre-clinical efficacy extrapolating human conditions with STC-1010
April 9, 2026
Scientific publications
#AACRIO26 : Brenus presents new translational preclinical datas and early clinical safety datas
February 19, 2026
Press
#AACRIO26 : Brenus presents new translational preclinical datas and early clinical safety datas
February 19, 2026
Event
Winner of Pfizer x Biolabs Golden Ticket
February 6, 2026
Media
PHARMA MINDS – “Build a success biotech” with Marc de Garidel (Abivax CEO)
January 29, 2026
Press
Le Monde – JPM26 Renewed euphoria in the biotech ecosystem
January 22, 2026
Scientific publications
Brenus Pharma reports favorable tolerability and clinical signals in early preliminary results of first-in-human study for STC-1010 in unresectable metastatic stage MSS CRC patients
January 6, 2026
Media
SACHS BEF 2025 – Advanced Oncology Investment Panel with Paul Bravetti
November 15, 2025
Press
Welcome Prof. Olivera J. Finn (USA) to our scientific advisory board
November 12, 2025
Event
Meet Brenus at JP Morgan annual Healthcare conference, San Francisco – 11, 15 Jan 2026
October 25, 2025
Event
Meet Brenus at Inv€$tival Showcase, London – 17 nov 2025
October 14, 2025
Media
BIG BPI – Brenus Pharma took part in the roundtable: “The French biotech ecosystem conquering European markets“
October 1, 2025
Press
Brenus Pharma announces first patients dosed in its first-in-human trial evaluating STC-1010, a next-generation immunotherapy
September 2, 2025
Media
L’ECHO – A world first for Brenus Pharma, the French biotech with a Belgian touch
September 2, 2025
Media
LES ECHOS – Brenus Pharma treats its first patients with its next-generation immunotherapy
September 2, 2025
Press
Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 global cancer stream, in partnership with north American universities
June 27, 2025
Press
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
May 7, 2025
Scientific publications
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
March 7, 2025
Scientific publications
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
November 7, 2024
Press
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
November 7, 2024
Media
BIG BPI – Brenus Pharma took part in the roundtable “Biotherapies: What potential for technology platforms?”
October 7, 2024
Media
BIO SPACE – Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Anti-cancer immunotherapy
September 20, 2024
Press
BFM TV – Brenus Pharma, the future of cancer treatment ?
September 18, 2024
Press
Brenus Pharma raises $25 million to accelerate clinical trials of its precision anticancer immunotherapy
September 18, 2024
Media
LES ECHOS – Brenus Pharma raises €22 million to launch clinical trials
September 18, 2024
Media
THE TIMES MAGAZINE – Brenus Pharma secures $25 million to propel clinical trials for precision anticancer immuotherapy
September 1, 2024
Press
Brenus Pharma wins French Tech Saint-Etienne Lyon’s BIG start-up of the year award
July 3, 2024
Scientific publications
#ASCO2024 Brenus Pharma presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA trial of STC-1010
June 13, 2024
Press
#ASCO2024 Brenus Pharma presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA trial of STC-1010
June 13, 2024
Press
#AACR2024 Brenus Pharma unveils promising and robust pre-clinical efficacy extrapolating human conditions with STC-1010
April 9, 2024
Press
France Biotech unveils the winners of the 2024 edition of the “HealthTech Trophies”: Spotlight on 9 innovative healthcare companies!
March 27, 2024
Press
Brenus Pharma, winner of the call for proposals “Innovations in biotherapies and bioproduction for France 2030”, receives €5 Million for its anticancer immunotherapy
January 22, 2024
Press
Brenus Pharma joins the Paris Saclay Cancer Cluster (PSCC) to collaborate at the heart of innovation in oncology
December 14, 2023
Scientific publications
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses
September 28, 2023
Press
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses
September 28, 2023
Press
Brenus Pharma announces its international scientific committee
June 7, 2023
Media
PHARMA MINDS – Taking the Leap: Paul Bravetti on Biotech, Risk & Innovation
June 6, 2023
Scientific publications
#AACR2023 Brenus Pharma unveils groundbreaking preclinical results For STC-10101, a promising new drug candidate targeting colorectal cancer & solid tumors
April 27, 2023
Press
#AACR2023 Brenus Pharma unveils groundbreaking preclinical results For STC-10101, a promising new drug candidate targeting colorectal cancer & solid tumors
April 27, 2023
Press
French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer
March 27, 2023
Press
Brenus Pharma announces its strategic committee supporting & ensuring its value-creating strategic plan
March 1, 2023
Media
LA TRIBUNE DE LYON – Lyon-based biotech Brenus Pharma raises €4 million to innovate against cancer
March 17, 2022
Media
LE POINT – Brenus Pharma: revolutionary therapies against cancer
November 20, 2020
Media
PHARMA MINDS – “Build a success biotech” with Marc de Garidel (Abivax CEO)
January 29, 2026
Media
SACHS BEF 2025 – Advanced Oncology Investment Panel with Paul Bravetti
November 15, 2025
Media
BIG BPI – Brenus Pharma took part in the roundtable: “The French biotech ecosystem conquering European markets“
October 1, 2025
Media
L’ECHO – A world first for Brenus Pharma, the French biotech with a Belgian touch
September 2, 2025
Media
LES ECHOS – Brenus Pharma treats its first patients with its next-generation immunotherapy
September 2, 2025
Media
BIG BPI – Brenus Pharma took part in the roundtable “Biotherapies: What potential for technology platforms?”
October 7, 2024
Media
BIO SPACE – Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Anti-cancer immunotherapy
September 20, 2024
Media
LES ECHOS – Brenus Pharma raises €22 million to launch clinical trials
September 18, 2024
Media
THE TIMES MAGAZINE – Brenus Pharma secures $25 million to propel clinical trials for precision anticancer immuotherapy
September 1, 2024
Media
PHARMA MINDS – Taking the Leap: Paul Bravetti on Biotech, Risk & Innovation
June 6, 2023
Media
LA TRIBUNE DE LYON – Lyon-based biotech Brenus Pharma raises €4 million to innovate against cancer
March 17, 2022
Media
LE POINT – Brenus Pharma: revolutionary therapies against cancer
November 20, 2020
Press
#AACRIO26 : Brenus presents new translational preclinical datas and early clinical safety datas
February 19, 2026
Press
Le Monde – JPM26 Renewed euphoria in the biotech ecosystem
January 22, 2026
Press
Welcome Prof. Olivera J. Finn (USA) to our scientific advisory board
November 12, 2025
Press
Brenus Pharma announces first patients dosed in its first-in-human trial evaluating STC-1010, a next-generation immunotherapy
September 2, 2025
Press
Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 global cancer stream, in partnership with north American universities
June 27, 2025
Press
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
May 7, 2025
Press
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
November 7, 2024
Press
BFM TV – Brenus Pharma, the future of cancer treatment ?
September 18, 2024
Press
Brenus Pharma raises $25 million to accelerate clinical trials of its precision anticancer immunotherapy
September 18, 2024
Press
Brenus Pharma wins French Tech Saint-Etienne Lyon’s BIG start-up of the year award
July 3, 2024
Press
#ASCO2024 Brenus Pharma presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA trial of STC-1010
June 13, 2024
Press
#AACR2024 Brenus Pharma unveils promising and robust pre-clinical efficacy extrapolating human conditions with STC-1010
April 9, 2024
Press
France Biotech unveils the winners of the 2024 edition of the “HealthTech Trophies”: Spotlight on 9 innovative healthcare companies!
March 27, 2024
Press
Brenus Pharma, winner of the call for proposals “Innovations in biotherapies and bioproduction for France 2030”, receives €5 Million for its anticancer immunotherapy
January 22, 2024
Press
Brenus Pharma joins the Paris Saclay Cancer Cluster (PSCC) to collaborate at the heart of innovation in oncology
December 14, 2023
Press
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses
September 28, 2023
Press
Brenus Pharma announces its international scientific committee
June 7, 2023
Press
#AACR2023 Brenus Pharma unveils groundbreaking preclinical results For STC-10101, a promising new drug candidate targeting colorectal cancer & solid tumors
April 27, 2023
Press
French Blood Establishment (EFS) & Brenus Pharma partner for the GMP production of STC-1010, an innovative therapy against colorectal cancer
March 27, 2023
Press
Brenus Pharma announces its strategic committee supporting & ensuring its value-creating strategic plan
March 1, 2023
Scientific publications
#AACR2024 Brenus Pharma unveils promising and robust pre-clinical efficacy extrapolating human conditions with STC-1010
April 9, 2026
Scientific publications
#AACRIO26 : Brenus presents new translational preclinical datas and early clinical safety datas
February 19, 2026
Scientific publications
Brenus Pharma reports favorable tolerability and clinical signals in early preliminary results of first-in-human study for STC-1010 in unresectable metastatic stage MSS CRC patients
January 6, 2026
Scientific publications
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
March 7, 2025
Scientific publications
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
November 7, 2024
Scientific publications
#ASCO2024 Brenus Pharma presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA trial of STC-1010
June 13, 2024
Scientific publications
Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses
September 28, 2023
Scientific publications
#AACR2023 Brenus Pharma unveils groundbreaking preclinical results For STC-10101, a promising new drug candidate targeting colorectal cancer & solid tumors
April 27, 2023
